Biogen Inc. Stock
€178.15
Your prediction
Biogen Inc. Stock
Pros and Cons of Biogen Inc. in the next few years
Pros
Cons
Performance of Biogen Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Biogen Inc. | -0.450% | -5.741% | -11.323% | -33.178% | -24.109% | -20.643% | -11.213% |
Pfizer Inc. | -0.190% | -2.851% | -6.654% | -35.541% | -8.621% | -25.863% | -28.239% |
Elanco Animal Health Inc. | -0.380% | -7.271% | -12.163% | 50.047% | -5.666% | -49.025% | - |
AbbVie Inc. | 0.100% | -0.909% | -5.831% | 6.410% | 10.435% | 71.797% | 123.293% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination, Biogen's financial health appears to be quite stable. The company demonstrates significant total assets backed by a strong shareholder equity. However, it's also essential to dig deeper into the financial landscape of this key player in the pharmaceutical industry to understand its true standing.
Strong Gross Profit: Biogen has consistently reported solid gross profits over the years. This is a positive sign as it indicates effective operations and significant markup on products, a crucial aspect of success within the pharmaceutical industry.
Substantial Assets and Equity: The company boasts noteworthy total assets and shareholder equity. This indicates that Biogen is well-capitalized and has substantial resources at its disposal to facilitate growth and tactical maneuvers in the market.
Comments
News
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen, (NASDAQ: BIIB) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311
Biogen (BIIB) Q4 2023 Earnings Call Transcript
Why Eli Lilly Stock Could Start Off 2024 With a Bang
Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years. The company is now the most valuable healthcare company in the world, with a valuation of around $550